Linkou Chang Gung Memorial Hospital

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

• Chang Gung Memorial Hospital, Linkou

  Taoyuan, 333423

  63 trials

• Linkou Chang Gung Memorial Hospital

  Taoyuan, 33305

  57 trials

• Chang Gung Memorial Hospital

  Taoyuan, 333

  43 trials

• Chang Gung Memorial Hospital Linkou

  Taoyuan City, 333

  42 trials

• Chang Gung Memorial Hospital, Linkou Branch

  Taoyuan, Guishan Dist 333423

  31 trials

• Linkou Chang-Gung Memorial Hospital

  Taoyuan City, 333

  22 trials

• Chang Gung Memorial Hospital, Linkou

  Taoyuan County, 333

  15 trials

• Chang Gung Memorial Hospital at Linkou

  Taoyuan, 33305

  10 trials

• Chang Gung Memorial Hospital

  Kaohsiung City, 886

  9 trials

• Chang Gung Memorial Hospital

  Taoyuan City, 333

  8 trials

• Chang Gung Memorial Hospital

  Linkou District, 333

  7 trials

• Chang Gung Memorial Hospital at Linkou

  Taoyuan City, Taiwan 333

  6 trials

• Chang Gung Memorial Hospital

  Taipei, 333

  5 trials

• Linkou Chang Gung Memorial Hospital (CGMHLK)

  Taoyuan City, 33305

  4 trials

• Chang Gung Memorial Hospital at Linkou

  Taipei, Taipei 10507

  3 trials

  • NCT07811193A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

  • NCT05457283A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

  • NCT05196035A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

• Chang Gung Memorial Hospital

  New Taipei City, 236

  2 trials

  • NCT06829095Personalized Nutrition Counseling and Nutritional Status of Esophageal Cancer and HNSCC Patients Undergoing CCRT

    Contact: Hsuan-Chih Kuo

  • NCT06917378TRIO CTO (Taiwan Research Initiative on Coronary Total Occlusion)

    Contact: Ying-Chang Tung, MD

• Chang Gung Memorial Hospital

  Chiayi City

  1 trial

  • NCT06502275Nutrition and Exercise Program for Elderly Colorectal Cancer Patients

    Contact: Ching-Ching Su, PhD

• Chang Gung Memorial Hospital

  Guishan, Taoyuan City 33305

  1 trial

  • NCT07660237Effects of a Transitional Care Program on Depression, Self-Efficacy, and Self-Care in Patients With Heart Failure

• Chang Gung Memorial Hospital

  Kaohsiung Country, 833

  1 trial

  • NCT05306340A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

• Chang Gung Memorial Hospital

  Mailiao, Yun Lin Hsien 63861

  1 trial

  • NCT06703151To Understand the Self-care Ability of Farmers and Fishermen With CMDs (Hypertension, Heart Disease, Hyperlipidemia, Type 2 Diabetes), Whether They Are Aware of CMDs, Their Treatment Status, Treatment Effectiveness, and Their Ability to Describe Known and Practice the Self-care Content of CMDs.

    Contact: Tung-Jung Huang, Dean

• Chang Gung Memorial Hospital

  Taoyuan County, 00333

  1 trial

  • NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

• Chang Gung Memorial Hospital - Linkou

  Taoyuan Hsien, 333

  1 trial

  • NCT02451943A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

• Chang Gung Memorial Hospital - Linkou

  Taoyuan, (r.o.c.), Taiwan 33342

  1 trial

  • NCT04666038Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

• Chang Gung Memorial Hospital- Linkou

  Taipei

  1 trial

  • NCT05659732A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer

    Contact: Hsiao-Wen Kao, MD

• Chang-Gung Memorial Hospital, Linkou

  Linkou District

  1 trial

  • NCT06495463Lonsurf® (Trifluridine/Tipiracil) Plus Chemotherapy in Metastatic Colorectal Cancer Prospective Study in Taiwan

• Chang Gung Memorial Hospitals, Linkou

  Taoyuan

  1 trial

  • NCT07248371Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases

    Contact: Chi-Hsiao Yeh, MD PhD

• Department of ENT, Linkou Chang Gung Memorial Hospital

  Taoyuan City, 33305

  1 trial

  • NCT07020689Transdisciplinary Intervention for Obesity Hypoventilation Syndrome

• Linkou Chang Gung Memorial Hospital

  Guishan, Taoyuan 333

  1 trial

  • NCT06831669Metabolomics to Predict Treatment Response and Toxicities in Rectal Cancer

    Contact: Eric Yi-Liang Shen, MD, PhD

• Linkou Chang Gung Memorial Hospital

  Guishan Dist, 33305

  1 trial

  • NCT03967977Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

• Linkou Chang Gung Memorial Hospital

  New Taipei City

  1 trial

  • NCT06397911Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

    Contact: Yu-Huei Huang, MD, PhD

• Linkou Chang Gung Memorial Hospital

  Taipei

  1 trial

  • NCT05008965Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

    Contact: Shu-Min Lin, MD

• Linkou Chang Gung Memorial Hospital (CGMHLK)

  Taoyuan, 333

  1 trial

  • NCT05241873(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

• Linkou Chang Gung Memorial Hospital - Clinical Trial Pharmacy

  Taoyuan City, 333

  1 trial

  • NCT05911295Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

• Linkou Chang Gung Memorial Hospital /ID# 169804

  Taoyuan City, 333

  1 trial

  • NCT03345823A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

• Linkou Chang Gung Memorial Hospital /ID# 203636

  Taoyuan City, 333

  1 trial

  • NCT02966756A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

• Linkou Chang Gung Memorial Hospital /ID# 205424

  Taoyuan City, 333

  1 trial

  • NCT03539536Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

• Linkou Chang Gung Memorial Hospital /ID# 213951

  Taoyuan City, 333

  1 trial

  • NCT04102020A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

• Linkou Chang Gung Memorial Hospital /ID# 218982

  Taoyuan City, 333

  1 trial

  • NCT04468984Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

• Linkou Chang Gung Memorial Hospital /ID# 218983

  Taoyuan City, 333

  1 trial

  • NCT04472598Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

• Linkou Chang Gung Memorial Hospital /ID# 222469

  Taoyuan City, 333

  1 trial

  • NCT04451772A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

• Linkou Chang Gung Memorial Hospital /ID# 222603

  Taoyuan City, 333

  1 trial

  • NCT04189614An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

• Linkou Chang Gung Memorial Hospital /ID# 222878

  Taoyuan City, 333

  1 trial

  • NCT03398135A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

• Linkou Chang Gung Memorial Hospital /ID# 225946

  Taoyuan City, 333

  1 trial

  • NCT04721015Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

• Linkou Chang Gung Memorial Hospital /ID# 241053

  Taoyuan City, 333

  1 trial

  • NCT04497597A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

• Linkou Chang Gung Memorial Hospital /ID# 241520

  Taoyuan City, 333

  1 trial

  • NCT05368558Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia

• Linkou Chang Gung Memorial Hospital /ID# 244756

  Taoyuan City, 333

  1 trial

  • NCT05081557A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

• Linkou Chang Gung Memorial Hospital /ID# 245709

  Taoyuan City, 333

  1 trial

  • NCT05507580A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

• Linkou Chang Gung Memorial Hospital /ID# 248716

  Taoyuan City, 333

  1 trial

  • NCT05029882Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

• Linkou Chang Gung Memorial Hospital /ID# 249257

  Taoyuan City, 333

  1 trial

  • NCT05601882A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

• Linkou Chang Gung Memorial Hospital /ID# 251654

  Taoyuan City, 333

  1 trial

  • NCT05782907Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

• Linkou Chang Gung Memorial Hospital /ID# 253674

  Taoyuan City, 333

  1 trial

  • NCT05822752Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

• Linkou Chang Gung Memorial Hospital /ID# 253775

  Taoyuan City, 333

  1 trial

  • NCT04818385Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan

• Linkou Chang Gung Memorial Hospital /ID# 254033

  Taoyuan City, 333

  1 trial

  • NCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

• Linkou Chang Gung Memorial Hospital /ID# 256091

  Taoyuan City, 333

  1 trial

  • NCT05978622Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant

• Linkou Chang Gung Memorial Hospital /ID# 256892

  Taoyuan City, 333

  1 trial

  • NCT06063967A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

• Linkou Chang Gung Memorial Hospital /ID# 257640

  Taoyuan City, 333

  1 trial

  • NCT06107413Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

• Linkou Chang Gung Memorial Hospital /ID# 258724

  Taoyuan City, 333

  1 trial

  • NCT06257875A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

• Linkou Chang Gung Memorial Hospital /ID# 258725

  Taoyuan City, 333

  1 trial

  • NCT06012240A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

• Linkou Chang Gung Memorial Hospital /ID# 259171

  Taoyuan City, 333

  1 trial

  • NCT06241313Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

• Linkou Chang Gung Memorial Hospital /ID# 259420

  Taoyuan City, 333

  1 trial

  • NCT06084481Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

• Linkou Chang Gung Memorial Hospital /ID# 261696

  Taoyuan City, 333

  1 trial

  • NCT06332534Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

• Linkou Chang Gung Memorial Hospital /ID# 262535

  Taoyuan City, 333

  1 trial

  • NCT06236438Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

• Linkou Chang Gung Memorial Hospital /ID# 263664

  Taoyuan City, 333

  1 trial

  • NCT06461897A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

• Linkou Chang Gung Memorial Hospital /ID# 264620

  Taoyuan City, 333

  1 trial

  • NCT06468228A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

• Linkou Chang Gung Memorial Hospital /ID# 265551

  Taoyuan City, 333

  1 trial

  • NCT03821935Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

• Linkou Chang Gung Memorial Hospital /ID# 265922

  Taoyuan City, 333

  1 trial

  • NCT06548542Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

• Linkou Chang Gung Memorial Hospital /ID# 266424

  Taoyuan City, 333

  1 trial

  • NCT06806293Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

• Linkou Chang Gung Memorial Hospital /ID# 267045

  Taoyuan City, 333

  1 trial

  • NCT06428019A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

• Linkou Chang Gung Memorial Hospital /ID# 267637

  Taoyuan City, 333

  1 trial

  • NCT06614192A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

• Linkou Chang Gung Memorial Hospital /ID# 267668

  Taoyuan City, 333

  1 trial

  • NCT06628310A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

• Linkou Chang Gung Memorial Hospital /ID# 268137

  Taoyuan City, 333

  1 trial

  • NCT06772623Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

• Linkou Chang Gung Memorial Hospital /ID# 269725

  Taoyuan City, 333

  1 trial

  • NCT06820463A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

• Linkou Chang Gung Memorial Hospital /ID# 272084

  Taoyuan City, 333

  1 trial

  • NCT06543914Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

• Linkou Chang Gung Memorial Hospital /ID# 273640

  Taoyuan City, 333

  1 trial

  • NCT06880744A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

• Linkou Chang Gung Memorial Hospital /ID# 277135

  Taoyuan City, 333

  1 trial

  • NCT07155187A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

• Linkou Chang Gung Memorial Hospital /ID# 277264

  Taoyuan City, 333

  1 trial

  • NCT07155174A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

• Linkou Chang Gung Memorial Hospital /ID# 278042

  Taoyuan City, 333

  1 trial

  • NCT07230288Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

• Linkou Chang Gung Memorial Hospital /ID# 279294

  Taoyuan City, 333

  1 trial

  • NCT07581002A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

• Linkou Chang Gung Memorial Hospital /ID# 279760

  Taoyuan City, 333

  1 trial

  • NCT07136467A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

    Contact: Beth Rycroft

• Linkou Chang Gung Memorial Hospital (Site 0502)

  Taoyuan, 333

  1 trial

  • NCT03040999Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

• Linkou Chang Gung Memorial Hospital (Site 1097)

  Taoyuan, 333

  1 trial

  • NCT04221945Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

• Linkou Chang Gung Memorial Hospital (Site 1901)

  Taoyuan, 333

  1 trial

  • NCT03884101Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

• Linkou Chang Gung Memorial Hospital (Site 2300)

  Taoyuan, 333

  1 trial

  • NCT03036488Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

• Linkou Chang Gung Memorial Hospital (Site 2501)

  Taoyuan, 333

  1 trial

  • NCT03740165Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

• Linkou Chang Gung Memorial Hospital (Site 2605)

  Taoyuan, 333

  1 trial

  • NCT07318558A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

    Contact: Study Coordinator

• Linkou Chang Gung Memorial Hospital (Site 3705)

  Taoyuan, 333

  1 trial

  • NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    Contact: Study Coordinator

• Linkou Chang Gung Memorial Hospital (Site 4091)

  Taoyuan, 33305

  1 trial

  • NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)